Cutia Therapeutics (CUTIA-B) has issued a circular convening its Annual General Meeting for 10:00 a.m. on 26 June 2026 at its Shanghai headquarters.

Key resolutions:

1. Board composition • Five directors—Non-executives Lu Minfang and Yang Yunxia, and Independent Non-executives Chung Ming Kit, Zhang Zhisong and Ye Xiaoxiang—will stand for re-election. • All five are eligible and have offered themselves for new three-year terms.

2. Capital mandates • Share Repurchase Mandate: Directors seek authority to buy back up to 36.34 million shares, equivalent to 10.0% of the company’s issued share capital excluding 1.36 million treasury shares (basis: 363.37 million shares outstanding as at 21 Apr 2026). • Issuance Mandate: Directors request authorisation to issue up to 72.67 million new shares, or 20.0% of the current issued share capital, with an option to extend by any shares repurchased under the buy-back mandate.

3. Auditor • Ernst & Young is nominated for re-appointment as external auditor for the financial year ending 31 Dec 2026, with remuneration to be set by the Board.

Administrative details • Shareholders’ register will close from 23 Jun to 26 Jun 2026; transfers must be lodged by 4:30 p.m. on 22 Jun 2026 to qualify for voting. • Proxy forms must be submitted to Tricor Investor Services by 10:00 a.m. on 24 Jun 2026.

Capital structure snapshot (21 Apr 2026): • Issued shares: 363.37 million • Treasury shares: 1.36 million

No director or connected person has signalled an intention to sell shares should the repurchase mandate be approved, and management states any buy-backs will be funded from legally available resources without materially affecting working-capital needs.

All resolutions will be decided by poll, with results disclosed via the Hong Kong Stock Exchange.